| Catalyst | Drug/Treatment | Stage | Probability of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology | ||
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology | ||
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology |
Recent Updates
Recently added Catalysts
Evolent Health, Inc Class A Common Stock$3.68
+0.59 (+19.32%)
Market Cap
412.24 M
EPS
-4.41
P/E Ratio
-
Value Trade
11.64 M
SEC Financials
Q1 2026Dilution Risk
Revenue
496.25 M
Operating CF
-984.00 K
Total Assets
1.88 B
Total Liabilities
1.48 B
Equity
396.39 M
14.31 %
Week
-33.67 %
1 Month
-14.87 %
3 Month
25.78 %
6 Month
%
5 Year
%
All Time
Cash Data
Cash Position
168.74 M
Monthly Burn
328.00 K
Runway
511.5 mo
Burn Trend
SEC Filing
May 7, 2026
Overview
Volume
3.10 M
52 Week Range
2.10 - 10.08
% held by Insiders
4.27 %
% held by Institutions
94.18 %
Enterprise Value
1.22 B
Total Shares
112.53 M
Short %
14.03 %
Float Shares
104.65 M
Company Description
locked
Upcoming Catalyst
Past FDA Catalysts & PDUFA Decisions
| Date | Drug | Catalyst | Stage | Outcome | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|---|
— | Example Drug | Phase 3 data readout | Phase 3 | — | – | 0% | 0% |
— | Example Drug | Phase 3 data readout | Phase 3 | — | – | 0% | 0% |
— | Example Drug | Phase 3 data readout | Phase 3 | — | – | 0% | 0% |
Drug Pipeline Intelligence
Clinical Trial Results
| Drug Name | Indications | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
Example Drug | Example indication for clinical evaluation | Phase 3 | 2025-12-01 | The study met its primary endpoint demonstrating statistically significant improvement. Read More | Phase 3 Study Results Announcement | |
Example Drug | Example indication for clinical evaluation | Phase 3 | 2025-12-01 | The study met its primary endpoint demonstrating statistically significant improvement. Read More | Phase 3 Study Results Announcement | |
Example Drug | Example indication for clinical evaluation | Phase 3 | 2025-12-01 | The study met its primary endpoint demonstrating statistically significant improvement. Read More | Phase 3 Study Results Announcement |
Inside Trades
YEARLY INSIDER TRANSACTIONS
Sector Avg.
INSIDERS
SOLDINSIDERS
BOUGHT
SOLDINSIDERS
BOUGHT
POSITIVE SENTIMENT Based on 22 Insiders Transactions
Hedge Funds
Shares Held
HEDGE FUNDS
SOLDHEDGE FUNDS
BOUGHT
SOLDHEDGE FUNDS
BOUGHT
POSITIVE SENTIMENT Based on 27 hedge funds in the last quarter
18 buying (3 new)·9 selling (1 exited)·2 unchanged
Hedge Funds invested in EVH
| HedgeFund Name ( 3 ) | % of Portfolio | Current MV - | Shares Owned - | Activity Avg Price $0 |
|---|---|---|---|---|
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K |
EVH Institutional Ownership Trends
Current Insider %
5.20%
—+0.00%
Current Institutional %
62.40%
—+0.00%
Total Ownership
67.60%
Insider + Institutional
Data Points
1
1 Ticker(s)
Option Chain Statistics
| Expiration | Volume | Open Interest | Implied Volatility Calls | Implied Volatility Puts | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Calls | Puts | Put-Call Ratio | Calls | Puts | Put-Call Ratio | IV | OiWaIv | VWaIv | IV | OiWaIv | VWaIv | |
| 2027-03-19 | 0.00 | 0 | - | - | - | - | - | - | ||||
| 2027-03-19 | 0.00 | 0 | - | - | - | - | - | - | ||||
| 2027-03-19 | 0.00 | 0 | - | - | - | - | - | - | ||||
Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last Price | Volume | Open Interest | Last Price | Volume | Open Interest | |
| No data available | ||||||
Open interest
Today's Open Interest
1.00 M
Put-Call Ratio
1.1
Put Open Interest
480.00 K
Call Open Interest
520.00 K
Open Interest Avg (30-day)
900,000
Today vs Open Interest Avg (30-day)
11.11%
Option Volume
Today's Volume
750.00 K
Put-Call Ratio
0.95
Put Volume
360.00 K
Call Volume
390.00 K
Volume Avg (30-day)
800,000
Today vs Volume Avg (30-day)
-6.25%
Company News
-EVH
Aug 6, 2026▲ +19.3%today
Evolent Announces Second Quarter 2026 Results
Evolent Health, Inc. announced its financial results for Q2 2026, showcasing a revenue of $652.5 million, a significant increase from the previous year. The company anticipates over 25% revenue growth for 2027, driven by strong demand for its oncology solutions. Despite reporting a net loss, Evolent's adjusted EBITDA outlook remains positive, reflecting confidence in its operational model and partnerships. The company is also addressing industry challenges while focusing on improving financial flexibility.
Read more →-EVH
Jul 8, 2026Evolent To Release Second Quarter 2026 Financial Results on Thursday, August 6, 2026
Evolent Health, Inc. has announced that it will release its second quarter 2026 financial results on August 6, 2026, before the market opens. A conference call will follow at 8 a.m. ET, where shareholders and analysts can participate. The company emphasizes its commitment to improving healthcare outcomes for complex conditions.
Read more →-EVH
May 7, 2026▲ +11.5%on this news
Evolent Announces First Quarter 2026 Results WASHINGTON (
Evolent Health, Inc. announced its financial results for the first quarter of 2026, revealing a revenue increase to $496.2 million. The company significantly narrowed its net loss compared to the previous year. CEO Seth Blackley expressed satisfaction with the company’s progression, notably in oncology launches and new revenue agreements expected to yield substantial future revenues. However, a decrease in adjusted EBITDA margin indicates ongoing financial challenges.
Read more →-EVH
May 7, 2026▲ +11.5%on this news
Evolent Announces First Quarter 2026 Results
Evolent Health, Inc. reported its financial results for Q1 2026, showing a revenue increase to $496.2 million from $483.6 million in Q1 2025. The company experienced a net loss of $26.6 million, significantly reduced from $72.3 million a year prior. Evolent is focused on expanding its oncology market presence and leveraging AI opportunities while maintaining commitments to stakeholders. The company anticipates a revenue range of $2.4 billion to $2.6 billion for the full year.
Read more →-EVH
Feb 24, 2026▼ -7.6%on this news
Evolent Announces Fourth Quarter 2025 Results and Full Year 2025 Results WASHINGTON (
Evolent Health, Inc. reported its financial results for Q4 and the full year of 2025, highlighting a revenue of $468,719 for the quarter and $1,876,229 for the year. Despite achieving its earnings targets and strong customer retention, the company faced a substantial net loss of $429,131 in Q4. Evolent expects a robust revenue growth of 30% in 2026, underpinned by the anticipated addition of $900 million in new Performance Suite revenue, although challenges from declining customer memberships are anticipated in the first half of 2026. Overall, the company remains optimistic about market opportunities in its specialty model for healthcare delivery.
Read more →-EVH
Nov 6, 2025▼ -5.5%on this news· ran to -22% by day 1
Evolent Announces Third Quarter 2025 Results Q3 2025 financial results ahead of expectations. Announces more than $500 million in newly-contracted annualized revenue to launch in 2026. Expands leadership team to support
Evolent Health, Inc. announced its financial results for Q3 2025, showcasing revenue ahead of expectations. The company secured over $500 million in new annualized revenue from new contracts for 2026. Leadership changes were made to bolster growth, including the appointment of a new Chief Financial Officer. Despite positive contract growth and a solid product offering, the company still recorded a net loss.
Read more →-EVH
Sep 23, 2025Evolent Announces Strategic Divestiture of its Value-Based Primary Care Business, Evolent Care Partners Evolent reiterates outlook for Q3 2025 and full year 2025 for Revenue and Adjusted EBITDA, excluding the effect of t
Evolent Health, Inc. has announced the divestiture of its value-based primary care business, Evolent Care Partners, to Privia Health Group for up to $113 million. The transaction is aimed at focusing Evolent's operations on its core specialty business, while also improving cash flow by over $7 million annually following debt repayment. Evolent has reiterated its revenue and EBITDA outlook for Q3 and full year 2025, indicating stability in financial expectations despite the asset sale.
Read more →-EVH
Aug 19, 2025Evolent Health, Inc. Announces Pricing of Oversubscribed and Upsized $145.0 Million of Convertible Senior Notes Due 2031 to Repurchase Existing Notes and Class A Common Stock WASHINGTON
Evolent Health, Inc. announced the pricing of $145 million in convertible senior notes due 2031, aimed at repurchasing existing notes and Class A common stock. The oversubscribed offering, initially set at $140 million, has increased in size, indicating strong investor interest. The chief financial officer highlighted that the transaction will help reduce annual interest expenses and manage shareholder dilution. The net proceeds are projected to facilitate repurchase activities, enhancing the company's financial position.
Read more →-EVH
Aug 18, 2025Evolent Health, Inc. Announces Proposed Offering of $140.0 Million of Convertible Senior Notes Due 2031 to Repurchase Existing Notes and Class A Common Stock WASHINGTON
Evolent Health, Inc. has announced a proposed offering of $140 million in convertible senior notes due in 2031. The proceeds from the offering will be primarily used to repurchase existing convertible senior notes and Class A common stock. The initiative aims to enhance the company's financial position, although the successful execution of the offering is contingent on market conditions. Additionally, the share repurchase may lead to shareholder dilution concerns.
Read more →-EVH
Aug 7, 2025Evolent Announces Second Quarter 2025 Results WASHINGTON (
Evolent Health, Inc. reported its financial results for the second quarter of 2025, showing a significant increase in net loss compared to the previous year while exceeding EBITDA targets and raising its profitability outlook. The company is experiencing rapid growth in its business pipeline and aims to innovate further in the healthcare space through AI solutions. However, revenue has decreased compared to the same period last year, highlighting ongoing challenges in the health industry. Evolent anticipates continued strong customer retention and projects increased revenue for the full year.
Read more →-EVH
Jun 20, 2025▲ +6.9%on this news· ran to +24% by day 3
Evolent reiterates Q2 and full year guidance for Adjusted EBITDA Notes accelerating 2026 revenue bookings forecast Secures incremental non-dilutive financing WASHINGTON
Evolent Health, Inc. has reiterated its Q2 2025 Adjusted EBITDA guidance of $33M-$40M and full year guidance of $135M-$165M, citing positive oncology cost trends. The company has secured a Commitment Letter for additional non-dilutive capital which will aid in managing its capital needs related to a forecasted increase in revenue bookings for 2026. Evolent's leadership expresses confidence in meeting financial expectations, bolstered by favorable operational indicators.
Read more →-EVH
May 8, 2025Evolent Announces First Quarter 2025 Results WASHINGTON (
Evolent Health, Inc. announced its financial results for the first quarter of 2025, showing a net loss of $72.3 million, which represents a decline compared to $25.2 million reported in the same period last year. Despite this, the company achieved revenue of $483.6 million and noted a strong selling environment, with five new revenue agreements. Evolent reiterated its revenue outlook for the full year 2025, expecting revenue between $2.06 billion to $2.11 billion, while focusing on enhancing specialty care solutions.
Read more →-EVH
Apr 22, 2025Evolent names Shawn Guertin as new independent nominee for election to its Board of Directors Former CFO of CVS Health, Aetna and Coventry Health Care brings deep experience driving growth and profitability. Mr. Guertin'
Evolent Health has nominated Shawn Guertin for election to its Board of Directors at the upcoming annual meeting. Guertin, who has extensive experience in the health care industry, most recently served as CFO of CVS Health. His nomination aligns with Evolent's ongoing efforts to refresh its board and enhance governance practices. If elected, he would succeed Diane Holder, who is stepping down after 14 years.
Read more →-EVH
Feb 20, 2025Evolent Announces Fourth Quarter and Full Year 2024 Results Revenue of $646.5 million for the three months ended
Evolent Health, Inc. reported financial results for Q4 and full year 2024, achieving revenues of $646.5 million for the quarter and $2.55 billion for the year, reflecting significant growth compared to 2023. Despite this achievement, the company posted a net loss of $30.6 million for the quarter and $93.5 million for the year, with net loss margins of (4.7)% and (3.7)%, respectively. Evolent highlighted a successful contract retention strategy, achieving 100% retention among top customers. Looking ahead, the company anticipates an improvement in its financial outlook through contract adjustments and growth in complex care solutions.
Read more →-EVH
Feb 4, 2025Evolent Health Announces Changes to Board of Directors Richard "Rick" Jelinek to Be Named Chair of the Board at 2025 Annual Meeting Company Continues Board Refreshment Efforts with Brendan Springstubb's Appointment as Ne
Evolent Health has announced significant changes to its Board of Directors, appointing Rick Jelinek as Chair, effective at the 2025 Annual Meeting. Brendan Springstubb has joined the board as an independent director, bringing extensive experience in healthcare investments. This move is part of Evolent’s ongoing efforts to refresh its board and strengthen corporate governance, with plans for further director appointments ahead of the upcoming annual meeting.
Read more →-EVH
Nov 7, 2024Evolent Announces Third Quarter 2024 Results Revenue of $621.4 million, an increase of $110.4 million or 21.6% , from the three months ended
Evolent Health, Inc. reported third-quarter 2024 revenue of $621.4 million, up by 21.6% from the previous year. However, the company faced a net loss of $31.2 million and a decrease in Adjusted EBITDA. Despite challenges, Evolent announced six new record contract agreements and expresses optimism about future growth in specialty care solutions. The financial outlook for the fourth quarter and full year has been adjusted to reflect anticipated revenue and EBITDA targets.
Read more →-EVH
Aug 8, 2024Evolent Announces Second Quarter 2024 Results Revenue of $647.1 million, an increase of $178.0 million or 37.9% , from the three months ended
Evolent Health, Inc. reported strong financial results for Q2 2024, with revenue of $647.1 million representing a 37.9% increase from the previous year. Despite a net loss of $6.4 million, the company highlighted consistent profitability and positive cash flow. The firm also narrows its revenue outlook for FY 2024, projecting approximately $2.56 billion to $2.60 billion in revenue. CEO Seth Blackley expressed confidence in meeting adjusted EBITDA guidance and underscored successful new revenue agreements.
Read more →-EVH
Jun 4, 2024Document Evolent signs agreement to acquire artificial intelligence utilization management products and team from Machinify Machinify solution seeks to accelerate the efficiency, quality, and clinical value of Evolent's
Evolent Health, Inc. has signed an agreement to acquire artificial intelligence-based utilization management products and the team from Machinify. This acquisition is intended to enhance the efficiency and clinical quality of Evolent's specialty management platform through AI-enabled automation. The deal includes a proven software platform, Machinify Auth, which is expected to significantly reduce clinician workload and streamline data management. The acquisition is set to close in the third quarter of 2024 and is anticipated to bring added value to Evolent's client base.
Read more →-EVH
May 9, 2024Evolent Announces First Quarter 2024 Results Revenue of $639.7 million, an increase of $212.0 million or 49.6%, from the three months ended
Evolent Health, Inc. reported strong financial results for the first quarter of 2024, with revenue of $639.7 million, a 49.6% increase from the same period last year. Despite facing a net loss of $25.2 million, the company raised its revenue outlook for the full year and reiterated its Adjusted EBITDA guidance. The company also highlighted successful integration efforts post-acquisition and advancements in patient navigation and artificial intelligence through strategic partnerships. However, challenges in the health plans sector were acknowledged, impacting their overall financial metrics.
Read more →-EVH
Feb 22, 2024Evolent Health, Inc. Consolidated Statements of Operations and Comprehensive Income (Loss) (unaudited, in thousands, except per share data) For the Three Months Ended December 31, For the Year Ended
Evolent Health, Inc. has reported its financial results for the fourth quarter and full year of 2023, showcasing a 45% growth in revenue compared to the previous year, totaling $1.963 billion. Despite achieving strong earnings, the company recorded a net loss of $142.3 million for the year. Evolent announced new revenue agreements and provided an optimistic outlook for 2024, forecasting a revenue increase of 25%. However, concerns regarding higher net loss margins pose challenges for profitability moving forward.
Read more →-EVH
Feb 14, 2024Document Evolent Adds Russell Glass, Headspace CEO, to Board of Directors WASHINGTON
Evolent Health has appointed Russell Glass, the current CEO of Headspace, to its Board of Directors, filling the vacancy left by Dr. Tunde Sotunde's retirement. Glass is recognized for his significant experience in healthcare technology and mental health solutions, which Evolent aims to leverage in improving patient care. Evolent's CEO praised Glass's capabilities to guide the company in its evolving value-based specialty care platform, highlighting a commitment to affordability and access in healthcare.
Read more →-EVH
Dec 5, 2023▼ -9.1%on this news
Evolent Health, Inc. Announces Proposed Offering of $350.0 Million of Convertible Senior Notes Due 2029 to Pay Down Senior Term Loan WASHINGTON
Evolent Health, Inc. announced the proposed offering of $350 million in convertible senior notes due 2029, aimed at paying down its senior term loan. The offering is contingent on market conditions and will only be available to qualified institutional buyers. Proceeds will be utilized for repaying loans, with an option for additional notes to further reduce outstanding debt. Evolent is known for its commitment to improving health outcomes and maintaining affordable healthcare solutions.
Read more →-EVH
Dec 5, 2023▼ -9.1%on this news
Evolent Health, Inc. Announces Pricing of $350.0 Million of Convertible Senior Notes Due 2029 to Pay Down Senior Term Loan WASHINGTON
Evolent Health, Inc. announced the pricing of $350 million in convertible senior notes due in 2029, aimed at paying down its senior term loan. The notes come with a 3.50% interest rate, payable semiannually starting in June 2024. Evolent may use the proceeds to prepay part of its outstanding borrowings under its term loan facility maturing in January 2029. The offering is restricted to qualified institutional buyers as per SEC regulations and is subject to customary closing conditions.
Read more →-EVH
Nov 3, 2023▲ +13.5%on this news
COMBINED FINANCIAL STATEMENTS MAGELLAN SPECIALTY HEALTH (A Business of Magellan Health, Inc.)
Magellan Specialty Health, a division of Magellan Health, Inc., published its combined financial statements for the year ending December 31, 2022. The audit confirmed that the financial statements fairly represent the company's financial position, showing a net income of $42.261 million. However, the company also experienced significant financial outflows to its parent, raising concerns about liquidity. Total liabilities amounted to $15.428 million against total assets of $161.763 million, reflecting the company's operational framework.
Read more →-EVH
Nov 2, 2023Evolent Announces Third Quarter 2023 Results WASHINGTON (
Evolent Health, Inc. announced its financial results for the third quarter of 2023, highlighting a 44.9% revenue increase to $511 million. The company reported a net loss of $33.2 million but achieved significant growth in specialty care offerings, with an 80% increase compared to the previous year. Evolent is also expanding its service offerings, planning to launch a new cardiology suite in partnership with Florida Blue in early 2024. Additionally, the firm raised its adjusted EBITDA guidance for the year, indicating a positive outlook despite current losses.
Read more →-EVH
Aug 2, 2023Evolent Announces Second Quarter 2023 Results WASHINGTON (
Evolent Health, Inc. reported its second quarter 2023 results, showcasing a significant revenue increase of 46.6%, amounting to $469.1 million. Despite the positive revenue growth, the company experienced a net loss of $41.4 million, highlighting challenges in managing expenses. Evolent has signed six new operating partnerships this year, and its Adjusted EBITDA improved to $47.4 million. The company is optimistic, raising its Adjusted EBITDA guidance based on encouraging marketplace receptivity to its integrated approach to specialty care.
Read more →-EVH
May 23, 20231.95B 2023 Revenue Outlook at Midpoint 39%1 Revenue CAGR Q4 2019 - Q1 2023 $190M1 2023 Adjusted EBITDA Outlook at Midpoint ~110% Revenue Renewal Rate (2022) $50B Cross-Sell Revenue Opportunity out of $150B Specialty TAM
Evolent Health has outlined an optimistic outlook for 2023, projecting revenue at $1.95 billion with a compound annual growth rate of 39% from Q4 2019 through Q1 2023. The company expects an adjusted EBITDA margin of around 110%, showcasing its capability in maintaining strong profitability. Additionally, a high revenue renewal rate reflects sustained client loyalty while also identifying a substantial cross-sell opportunity within the burgeoning specialty market. Overall, Evolent Health is positioning itself for significant growth amid a competitive landscape.
Read more →-EVH
May 3, 2023Evolent Health Announces First Quarter 2023 Results WASHINGTON (
Evolent Health reported strong financial results for the first quarter of 2023, with a 44% increase in revenue, reaching $427.7 million. The company faced a net loss of $26.3 million, marking a deterioration in its net loss margin compared to the previous year. Total Lives on Platform rose to 65.6 million, showcasing substantial growth in user engagement. Additionally, Evolent expanded its partnerships with key players like Centene, positioning itself for continued revenue growth.
Read more →-EVH
Apr 19, 2023Evolent Health Names New Independent Nominee for Election to Board of Directors Richard Jelinek nominated to join the Board current director David Farner to depart the Board in June 2023, in addition to previously announ
Evolent Health, Inc. has nominated Richard Jelinek as an independent director for election at the annual stockholders' meeting on June 8, 2023. Jelinek has significant experience in the health care sector, having held key executive roles at Aetna, CVS Health, and OptumHealth. This announcement comes alongside the resignations of current directors David Farner and Frank Williams, which marks a notable shift in the Board’s composition. Evolent aims to leverage Jelinek's insights as it pursues leadership in value-based specialty care.
Read more →-EVH
Feb 22, 2023Evolent Health Announces Fourth Quarter and Full Year 2022 Results WASHINGTON (
Evolent Health, Inc. announced its financial results for the fourth quarter and full year of 2022, reporting a substantial revenue increase of 54.0% in Q4 compared to the previous year, reaching $382.4 million. Despite this growth, the company faced a net loss attributable to common shareholders of $11.3 million, though this was an improvement from previous losses. The company is optimistic about 2023, having signed significant new operating partnerships that are projected to generate over $250 million in additional revenue next year. Evolent's total lives on their platform also expanded to 20.6 million, highlighting their growth in market reach.
Read more →-EVH
Jan 11, 2023Safe Harbor Statement Certain statements, including but not limited to estimates of Adjusted EBITDA, earnings growth, expected cost synergies and net leverage ratios, made in this presentation and in other written or ora
The presentation discusses forward-looking statements related to financial projections and strategies for the future of EVH. It highlights potential risks and uncertainties that could affect performance, including the possibility of delays in the NIA transaction and reliance on major partners for revenue. The document also advises investors not to rely solely on these forward-looking statements due to the unpredictable nature of the market and emerging risk factors. Investors are encouraged to review related SEC filings for further details on potential impacts.
Read more →-EVH
Nov 10, 2022▲ +7%on this news
Safe Harbor Statement Certain statements made in this presentation and in other written or oral statements made by us or on our behalf are "forward-looking statements" within the meaning of the Private Securities Litigat
Confidential - Do Not Distribute1 Evolent Health, Inc. Supplemental Investor Presentation November 9, 2022 Exhibit 99.1 2 Safe Harbor Statement Certain statements made in this presentation and in other written or oral statements made by us or on our behalf are "forward-looking s
Read more →-EVH
Nov 2, 2022Evolent Health Announces Third Quarter 2022 Results WASHINGTON (
Evolent Health Announces Third Quarter 2022 Results WASHINGTON (November 2, 2022) - Evolent Health, Inc. (NYSE EVH), a health care company that delivers proven clinical and administrative solutions to payers and providers, today announced financial results for the quarter ended
Read more →-EVH
Aug 2, 2022Evolent Health Announces Second Quarter 2022 Results Announces Four Operating Partner Additions WASHINGTON (
Evolent Health Announces Second Quarter 2022 Results Announces Four Operating Partner Additions WASHINGTON (August 2, 2022) - Evolent Health, Inc. (NYSE EVH), a health care company that delivers proven clinical and administrative solutions to payers and providers, today announc
Read more →-EVH
Jun 29, 2022EVOLENT HEALTH TO ACQUIRE IPG - Expected to Accelerate Evolent Health's Position as a Leading Provider of Value-Based Specialty Care Solutions - Expands Evolent's Value-Based Specialty Care Solutions Portfolio to Musculo
EVOLENT HEALTH TO ACQUIRE IPG - Expected to Accelerate Evolent Health's Position as a Leading Provider of Value-Based Specialty Care Solutions - Expands Evolent's Value-Based Specialty Care Solutions Portfolio to Musculoskeletal Conditions - Expected to be Immediately Accretiv
Read more →-EVH
May 4, 2022Evolent Health Announces First Quarter 2022 Results Announces Two Operating Partner Additions and One Expansion WASHINGTON (
Evolent Health Announces First Quarter 2022 Results Announces Two Operating Partner Additions and One Expansion WASHINGTON (May 4, 2022) - Evolent Health, Inc. (NYSE EVH), a health care company that delivers proven clinical and administrative solutions to payers and providers,
Read more →-EVH
Feb 23, 2022Evolent Health Announces Fourth Quarter and Full Year 2021 Results Announces Four New Partner Additions Washington, D.C., (
Evolent Health Announces Fourth Quarter and Full Year 2021 Results Announces Four New Partner Additions Washington, D.C., (February 23, 2022) - Evolent Health, Inc. (NYSE EVH), a health care company that delivers proven clinical and administrative solutions to payers and provid
Read more →-EVH
Nov 3, 2021Evolent Health Announces Third Quarter 2021 Results Washington, D.C., (
Evolent Health Announces Third Quarter 2021 Results Washington, D.C., (November 3, 2021) - Evolent Health, Inc. (NYSE EVH), a health care company that delivers proven clinical and administrative solutions to payers and providers, today announced financial results for the quarter
Read more →-EVH
Aug 4, 2021Evolent Health Announces Agreement to Acquire Vital Decisions, Expanding its Depth and Breadth in Specialty Care Management The addition of Vital Decisions' specialized patient engagement services expected to position Ne
Evolent Health Announces Agreement to Acquire Vital Decisions, Expanding its Depth and Breadth in Specialty Care Management The addition of Vital Decisions' specialized patient engagement services expected to position New Century Health to accelerate growth, improve patient care
Read more →-EVH
May 5, 2021Evolent Health Announces First Quarter 2021 Results Washington, D.C., (
Evolent Health Announces First Quarter 2021 Results Washington, D.C., (May 5, 2021) - Evolent Health, Inc. (NYSE EVH), a health care company that delivers proven clinical and administrative solutions to payers and providers, today announced financial results for the quarter ende
Read more →-EVH
Feb 25, 2021Evolent Health Announces Fourth Quarter and Full Year 2020 Results Washington, D.C., (
Evolent Health Announces Fourth Quarter and Full Year 2020 Results Washington, D.C., (February 25, 2021) - Evolent Health, Inc. (NYSE EVH), a health care company that delivers proven clinical and administrative solutions to payers and providers, today announced financial results
Read more →-EVH
Jan 13, 2021Evolent Health Enters Agreement with Bright HealthCare for Bright HealthCare to Acquire True Health New Mexico WASHINGTON
Evolent Health Enters Agreement with Bright HealthCare for Bright HealthCare to Acquire True Health New Mexico WASHINGTON, January 13, 2021 -- Evolent Health, Inc. (NYSE EVH) (the Company or Evolent ), a health care company that delivers proven clinical and administrative soluti
Read more →-EVH
Dec 22, 2020Evolent Health Announces Cooperation Agreement With Engaged Capital Appoints New Independent Director Craig Barbarosh to the Board Board to Form a Strategy Committee Focused on Value Creation Initiatives Company to Seek
Evolent Health Announces Cooperation Agreement With Engaged Capital Appoints New Independent Director Craig Barbarosh to the Board Board to Form a Strategy Committee Focused on Value Creation Initiatives Company to Seek Stockholder Approval to Declassify Board at 2021 Annual M
Read more →-EVH
Nov 5, 2020Evolent Health Announces Third Quarter 2020 Results Washington, D.C., (
Evolent Health Announces Third Quarter 2020 Results Washington, D.C., (November 5, 2020) - Evolent Health, Inc. (NYSE EVH), a health care company that delivers proven clinical and administrative solutions to payers and providers, today announced financial results for the quarter
Read more →-EVH
Aug 4, 2020Evolent Health Announces Second Quarter 2020 Results WASHINGTON, D.C.
Evolent Health Announces Second Quarter 2020 Results WASHINGTON, D.C., August 4, 2020 - Evolent Health, Inc. (NYSE EVH), a health care company that delivers proven clinical and administrative solutions to payers and providers, today announced financial results for the quarter en
Read more →-EVH
May 7, 2020Evolent Health Announces First Quarter 2020 Results WASHINGTON, D.C.
Evolent Health Announces First Quarter 2020 Results WASHINGTON, D.C., May 7, 2020 - Evolent Health, Inc. (NYSE: EVH), a health care company that delivers proven clinical and administrative solutions to payers and providers, today announced financial results for the quarter ended
Read more →-EVH
Feb 25, 2020Evolent Health Announces Fourth Quarter and Full Year 2019 Results WASHINGTON, D.C.
Evolent Health Announces Fourth Quarter and Full Year 2019 Results WASHINGTON, D.C., February 25, 2020 - Evolent Health, Inc. (NYSE: EVH), a health care company that delivers proven clinical and administrative solutions to payers and providers, today announced financial results
Read more →-EVH
Nov 5, 2019Evolent Health Announces Third Quarter 2019 Results WASHINGTON, D.C.
Evolent Health Announces Third Quarter 2019 Results WASHINGTON, D.C., November 5, 2019 - Evolent Health, Inc. (NYSE: EVH), a company providing an integrated value-based care platform to the nation's leading physician and payer organizations, today announced financial results for
Read more →-EVH
Aug 6, 2019Evolent Health Announces Second Quarter 2019 Results WASHINGTON, D.C.
Evolent Health Announces Second Quarter 2019 Results WASHINGTON, D.C., August 6, 2019 - Evolent Health, Inc. (NYSE: EVH), a company providing an integrated value-based care platform to the nation's leading physician and payer organizations, today announced financial results for
Read more →-EVH
May 29, 2019Evolent Health Expands Partnership with Passport Health Plan to Support Medicaid Beneficiaries in the Commonwealth of Kentucky Passport's owners select Evolent as Passport's long-term financial and operating partner for
Evolent Health Expands Partnership with Passport Health Plan to Support Medicaid Beneficiaries in the Commonwealth of Kentucky Passport's owners select Evolent as Passport's long-term financial and operating partner for the health plan joint venture. Evolent will contribute ca
Read more →-EVH
May 7, 2019Evolent Health Announces First Quarter 2019 Results WASHINGTON, D.C.
Evolent Health Announces First Quarter 2019 Results WASHINGTON, D.C., May 7, 2019 - Evolent Health, Inc. (NYSE: EVH), a company providing an integrated value-based care platform to the nation's leading physician and payer organizations, today announced financial results for the
Read more →-EVH
Mar 28, 2019Evolent Health, GlobalHealth and Kinderhook Industries Launch "True Health"
Evolent Health, GlobalHealth and Kinderhook Industries Launch "True Health" to Support Provider-Led Medicare Advantage Plans Newly established joint venture True Health partners with leading providers to offer Medicare Advantage plans in targeted geographies WASHINGTON, D.C.,
Read more →-EVH
Feb 26, 2019Evolent Health Announces Fourth Quarter and Full Year 2018 Results
Evolent Health Announces Fourth Quarter and Full Year 2018 Results WASHINGTON, D.C., February 26, 2019 - Evolent Health, Inc. (NYSE: EVH), a company providing an integrated value-based care platform to the nation's leading physician and payer organizations, today announced finan
Read more →-EVH
Nov 6, 2018Evolent Health Announces Third Quarter 2018 Results WASHINGTON, D.C.
Evolent Health Announces Third Quarter 2018 Results WASHINGTON, D.C., November 6, 2018 - Evolent Health, Inc. (NYSE: EVH), a company providing an integrated value-based care platform to the nation's leading health systems and physician organizations, today announced financial re
Read more →-EVH
Oct 23, 2018Evolent Health, Inc. Announces Exercise of Option to Purchase Additional Convertible Senior Notes Due 2025 WASHINGTON
Evolent Health, Inc. Announces Exercise of Option to Purchase Additional Convertible Senior Notes Due 2025 WASHINGTON, October 23, 2018 /PRNewswire/ -- Evolent Health, Inc. (NYSE: EVH), a company providing an integrated value-based care platform to the nation's leading health sy
Read more →-EVH
Oct 17, 2018Evolent Health, Inc.
Evolent Health, Inc. Announces Pricing of $150.0 Million of Convertible Senior Notes Due 2025 WASHINGTON, October 17, 2018 /PRNewswire/ -- Evolent Health, Inc. (NYSE: EVH), a company providing an integrated value-based care platform to the nation's leading health systems and phy
Read more →-EVH
Oct 2, 2018Evolent Health Completes Acquisition of New Century Health WASHINGTON, D.C.
Evolent Health Completes Acquisition of New Century Health WASHINGTON, D.C., October 2, 2018 - Evolent Health, Inc. (NYSE: EVH) - Evolent Health, Inc. ("Evolent"), a company providing an integrated value-based care platform to the nation's leading health systems and physician or
Read more →-EVH
Sep 12, 2018Evolent Health to Acquire New Century Health, Expanding its Specialty Care Management Capabilities The addition of New Century Health provides significant depth in managing high-cost specialty care for providers and paye
Evolent Health to Acquire New Century Health, Expanding its Specialty Care Management Capabilities The addition of New Century Health provides significant depth in managing high-cost specialty care for providers and payers WASHINGTON, D.C., September 12, 2018 - Evolent Health
Read more →-EVH
Aug 7, 2018Evolent Health Announces Second Quarter 2018 Results WASHINGTON, D.C.
Evolent Health Announces Second Quarter 2018 Results WASHINGTON, D.C., August 7, 2018 - Evolent Health, Inc. (NYSE: EVH), a company providing an integrated value-based care platform to the nation's leading health systems and physician organizations, today announced financial res
Read more →-EVH
May 9, 2018Evolent Health Announces First Quarter 2018 Results
Evolent Health Announces First Quarter 2018 Results WASHINGTON, D.C., May 9, 2018 - Evolent Health, Inc. (NYSE: EVH), a company providing an integrated value-based care platform to the nation's leading health systems and physician organizations, today announced financial results
Read more →-EVH
Feb 27, 2018Evolent Health Announces Fourth Quarter and Full Year 2017 Results
Evolent Health Announces Fourth Quarter and Full Year 2017 Results WASHINGTON, D.C., February 27, 2018 - Evolent Health, Inc. ("Evolent") (NYSE: EVH), a company providing an integrated value-based care platform to the nation's leading health systems and physician organizations,
Read more →-EVH
Jan 10, 2018Evolent Health Overview January 2018 Safe Harbor Statement Certain statements in this presentation and in other written or oral statements made by us or on our behalf are "forward-looking statements" within the meaning o
Evolent Health Overview January 2018 Safe Harbor Statement Certain statements in this presentation and in other written or oral statements made by us or on our behalf are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995 ("PS
Read more →-EVH
Jan 2, 2018Evolent Health Completes Acquisition of Assets from New Mexico Health Connections
Evolent Health Completes Acquisition of Assets from New Mexico Health Connections WASHINGTON, D.C., January 2, 2018 - Evolent Health, Inc. (NYSE: EVH) ("Evolent"), a company providing an integrated value-based care platform to the nation's leading health systems and physician or
Read more →-EVH
Dec 8, 2017Evolent Health and Premier Health Announce Termination of Agreement
Evolent Health and Premier Health Announce Termination of Agreement for Acquisition of Premier Health Plan WASHINGTON, D.C., December 8, 2017- Evolent Health, a company providing an integrated value-based care platform to the nation's leading health systems and physician organi
Read more →-EVH
Nov 2, 2017Evolent Health Announces Third Quarter 2017 Results
Evolent Health Announces Third Quarter 2017 Results WASHINGTON, D.C., November 2, 2017 - Evolent Health, Inc. (NYSE: EVH), a company providing an integrated value-based care platform to the nation's leading health systems and physician organizations, today announced financial re
Read more →-EVH
Sep 27, 2017Evolent Health Announces Proposed Expansion of Relationships in Illinois and New Mexico WASHINGTON, D.C.
Evolent Health Announces Proposed Expansion of Relationships in Illinois and New Mexico WASHINGTON, D.C., September 27, 2017 - Evolent Health, a company providing an integrated value-based care platform to the nation's leading health systems and physician organizations, today a
Read more →-EVH
Aug 7, 2017Evolent Health Announces Second Quarter 2017 Results
Evolent Health Announces Second Quarter 2017 Results WASHINGTON, D.C., August 7, 2017 - Evolent Health, Inc. (NYSE: EVH), a company providing an integrated value-based care platform to the nation's leading health systems and physician organizations, today announced financial res
Read more →-EVH
May 9, 2017Evolent Health Announces First Quarter 2017 Results
Evolent Health Announces First Quarter 2017 Results WASHINGTON, D.C., May 9, 2017 - Evolent Health, Inc. (NYSE: EVH), a company providing an integrated value-based care platform to the nation's leading health systems and physician organizations, today announced financial results
Read more →-EVH
Feb 28, 2017Evolent Health Announces Fourth Quarter and Full Year 2016 Results
Evolent Health Announces Fourth Quarter and Full Year 2016 Results WASHINGTON, D.C., Feb. 28, 2017 - Evolent Health, Inc. (NYSE: EVH), a company providing an integrated value-based care platform to the nation's leading health systems and physician organizations, today announced
Read more →-EVH
Nov 9, 2016Evolent Health Announces Third Quarter 2016 Results
Evolent Health Announces Third Quarter 2016 Results Washington, DC, (November 9, 2016) - Evolent Health, Inc. (NYSE: EVH), a company providing an integrated value-based care platform to the nation's leading health systems and physician organizations, today announced financial re
Read more →-EVH
Oct 3, 2016Evolent Health Completes Acquisition of Valence Health
Evolent Health Completes Acquisition of Valence Health The addition of Valence Health enhances Evolent's market-leading value-based care platform WASHINGTON, DC. October 3, 2016 -- Evolent Health, Inc. (NYSE: EVH), a company providing an integrated value-based care platform to
Read more →-EVH
Aug 4, 2016Evolent Health Announces Second Quarter 2016 Results
Evolent Health Announces Second Quarter 2016 Results Washington, DC, (August 4, 2016) - Evolent Health, Inc. (NYSE: EVH), a company providing an integrated value-based care platform to the nation's leading health systems and physician organizations, today announced financial res
Read more →-EVH
Jul 13, 2016Evolent Health to Acquire Valence Health, Extending Breadth and Depth
Evolent Health to Acquire Valence Health, Extending Breadth and Depth of Value-Based Care Offering The addition of Valence Health will enhance Evolent's market-leading value-based care platform for providers Washington, DC - July 13, 2016, Evolent Health, Inc. (NYSE:EVH) - Ev
Read more →-EVH
May 12, 2016SEC Exhibit Evolent Health Announces First Quarter 2016 Results Washington, DC, (
Evolent Health Announces First Quarter 2016 Results Washington, DC, (May 12, 2016) - Evolent Health, Inc. (NYSE: EVH), a company providing an integrated value-based care platform to the nation's leading health systems and physician organizations, today announced financial result
Read more →-EVH
Feb 25, 2016Evolent Health Announces Fourth Quarter and Full Year 2015 Results
Evolent Health Announces Fourth Quarter and Full Year 2015 Results Washington, DC (February 25, 2016) - Evolent Health, Inc. (NYSE: EVH), a company providing an integrated value-based care platform to the nation's leading health systems and physician organizations, today announc
Read more →-EVH
Nov 5, 2015Evolent Health Announces Third Quarter 2015 Results
Evolent Health Announces Third Quarter 2015 Results Washington, D.C., (November 5, 2015) - Evolent Health, Inc. (NYSE: EVH), a company providing an integrated value-based care platform to the nation's leading health systems and physician organizations, today announced financial
Read more →-EVH
Nov 3, 2015Evolent Health Elects Cheryl Scott to Board of Directors
Evolent Health Elects Cheryl Scott to Board of Directors Washington, D.C. (November 3, 2015) - Evolent Health, the leader in helping progressive health care systems build and own the path to value-based care, today announced Cheryl Scott has been elected to Evolent's board of di
Read more →-EVH
Sep 2, 2015Evolent Health Elects Kenneth A.
Evolent Health Elects Kenneth A. Samet to Board of Directors Washington, D.C. (September 2, 2015) - Evolent Health, the leader in helping progressive health care systems build and own the path to value-based care, today announced Kenneth A. Samet has been elected to Evolent's bo
Read more →-EVH
Aug 6, 2015Evolent Health, Inc. 800 North Glebe Road, # 500 Arlington, Virginia 22203 Evolent Health Announces Second Quarter 2015 Results Arlington, VA
Evolent Health, Inc. 800 North Glebe Road, # 500 Arlington, Virginia 22203 Evolent Health Announces Second Quarter 2015 Results Arlington, VA, August 6, 2015 - Evolent Health, Inc. (NYSE: EVH), a pioneer in value-based care, today announced financial results for the quarter
Read more →-EVH
Jun 10, 2015Evolent Health, Inc. Announces Closing of Initial Public Offering Washington, D.C. (
Evolent Health, Inc. Announces Closing of Initial Public Offering Washington, D.C. (June 10, 2015) Evolent Health, Inc. (NYSE: EVH) has closed its previously announced initial public offering of its Class A common stock. Evolent sold 13,225,000 shares of its Class A common stoc
Read more →-EVH
Jun 4, 2015Evolent Health, Inc. Announces Pricing of Initial Public Offering Washington, D.C. (
Evolent Health, Inc. Announces Pricing of Initial Public Offering Washington, D.C. (June 4, 2015) Evolent Health, Inc. (NYSE: EVH) has priced its initial public offering of 11,500,000 shares of Class A common stock at a price to the public of $17.00 per share. The underwriters
Read more →Competitive Position
How EVH ranks across every disease it competes inCompetitive Position is a premium feature
See how EVH ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial